Wick, W., IdBaih, A., Vieito Villar, M., Tabatabai, G., Stradella, A., Ghiringhelli, F., Burger, M., Mildenberger, I., Herrlinger, U., Touat, M., Wen, P., Wick, A., Gouttefangeas, C., Maia, A., Bonny, C., Paillarse, J., Fagerberg, J., & Reardon, D. (n.d.). 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study. Immuno-oncology technology, 16, . http://access.bl.uk/ark:/81055/vdc_100172070375.0x000011